Incubation could be performed at room temperature and the assay itself could be accomplished in 3 easy steps since this method does not require any pretreatment of specimen (to remove rheumatoid factor).
If possible, CDC recommends pretreatment of serum specimens with heat (56°C) combined with polyethylene glycol p-tert-octylphenyl ether (Triton X-100) at a concentration of 10 μL/mL of serum to reduce viral titer; however, 100% inactivation may not occur (21 ).
The method of immunohistochemistry (IHC) was utilized to examine the protein expression of H3K27me3 in 98 pretreatment biopsy specimens of ESCC and in 30 samples of normal esophageal mucosa.
However, the relationship between immunohistochemical expression of TS in pretreatment biopsy specimens of gastric cancer and the response to fluoropyrimidine-based chemotherapy has revealed conflicting results.
High expression of NANOG and positive expression of mutant p53 in the pretreatment biopsy specimens of patients with OSCC were associated with poor survival rates and unfavorable clinicopathological features.
In the present study, a human anti-mutant p53 antibody (Abcam™, ab32049), which does not recognize human wild-type p53 protein but does react with a synthetic peptide corresponding to human mutant p53 aa 1-100 (N terminal), was used to detect the mutated type of p53 in the pretreatment biopsy specimens of patients with OSCC.
Retrospective analysis of pretreatment specimens using allele-specific oligonucleotide PCR (ASO-PCR) was able to demonstrate low levels o000000f mutant cDNA in all four cases, indicating clonal selection.
Furthermore, because neo-adjuvant treatment has recently become the standard of care for patients with advanced OSCC, evaluation of pretreatment biopsy specimens is important.
Although this study has a limited number of cases and used only IHC in paraffin-embedded tissue specimens, the results suggest that co-detection of mutant p53 and high NANOG levels in the pretreatment biopsy specimens of patients with OSCC is directly associated with unfavorable clinicopathological tumor features and poor survival rates.
In the present study, the early transcription factor NANOG, the CSC marker CD44, and human mutant p53 were immunohistochemically investigated in the pretreatment biopsy specimens of 57 patients with OSCC to identify any relationship of their expression patterns with clinicopathological tumor features and patient prognosis.
